LifeMD, Inc.
NASDAQ:LFMDMedical - Pharmaceuticals
-$0.16 today
- Market cap
- $82.17M
- Beta
- 1.99
- P/E (TTM)
- -13.8
- EPS (TTM)
- -$0.34
Volume 0.80M
Average 1.04M
LFMD Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
LifeMD, Inc.NASDAQ: LFMD
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $45.05M fell 2.6% year over year, ahead of the -5.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 30.1% from the prior quarter. Over 3 fiscal years it compounded at +4.7% a year.
Context
- Selling, general & admin amounted to 74.2% of revenue in FY2025, down 8.5 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $183.32M (+27.3%) for the fiscal year ending Dec 2026, a step up from the -18.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $45.05M+30.1% QoQ
- Last fiscal yearDec 2025
- $144.01M-18.0% YoY
- LTMMar 2026
- $172.43M-5.1% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 144.01M USD
- Year-over-year change
- -18.0%
- 4-year CAGR
- +4.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 144.01M | -18.0% |
| FY2024 | 2024-12-31 | 175.68M | +37.1% |
| FY2023 | 2023-12-31 | 128.15M | +2.2% |
| FY2022 | 2022-12-31 | 125.33M | +2.7% |
| FY2021 | 2021-12-31 | 122.08M | — |
Selling, General & Admin vs competitors
How LFMD compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -5.1% is the 7th highest of 9, against a peer median of +5.4%.
- Selling, general & admin amounts to 78.6% of revenue for LFMD, versus a peer median of 57.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $172.43M USD | -5.1% | +4.7% | 78.6% | |
| LTM Mar 2026 | $109.87M USD | +6.7% | +8.3% | 31.8% | |
| LTM Mar 2026 | $91.48M USD | -7.4% | -9.4% | 115.0% | |
| LTM Apr 2026 | CA$90.78M CAD | -15.3% | +7.8% | 13.5% | |
| LTM Mar 2026 | $88.81M USD | +5.3% | +20.9% | 150.3% | |
| LTM Mar 2026 | $80.58M USD | +5.5% | -1.0% | 36.2% | |
| LTM Mar 2026 | $74.99M USD | +121.9% | +18.4% | 184.2% | |
| LTM Mar 2026 | $61.81M USD | +48.8% | +19.6% | 57.5% | |
| LTM Mar 2026 | $27.57M USD | — | -5.4% | 47.7% | |
| LTM Mar 2026 | $27.13M USD | -1.6% | -10.3% | 64.9% | |
| Peer median (excluding LFMD) | — | +5.4% | +7.8% | 57.5% | |
Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 92.88M | 119.03M | 152.55M | 212.45M | 194.06M |
| Cost of Revenue | 18M | 18.67M | 18.9M | 24.07M | 39.29M |
| Gross Profit | 74.88M | 100.37M | 133.65M | 188.39M | 154.76M |
| Gross Margin | 80.6% | 84.3% | 87.6% | 88.7% | 79.8% |
| Research & Development | 948.16K | 2.97M | 6.06M | 9.51M | 7.35M |
| Selling, General & Admin | 122.08M | 125.33M | 128.15M | 175.68M | 144.01M |
| Operating Expenses | 129.18M | 143.81M | 148.14M | 204.53M | 162.43M |
| Depreciation & Amortization | 355.87K | 1.09M | 6.6M | 9.49M | 7.31M |
| EBITDA | (57.94M) | (38.6M) | (8.21M) | (6.65M) | (1.52M) |
| EBITDA Margin | -62.4% | -32.4% | -5.4% | -3.1% | -0.8% |
| Operating Income | (54.3M) | (43.45M) | (14.49M) | (16.14M) | (7.67M) |
| Operating Margin | -58.5% | -36.5% | -9.5% | -7.6% | -4.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.02M | 1.28M | 2.6M | 2.18M | 1.36M |
| Other Income / Expenses | (7.02M) | (1.21M) | (2.92M) | (2.18M) | (2.52M) |
| Income Before Tax | (61.32M) | (44.66M) | (17.41M) | (18.33M) | (10.19M) |
| Pre-Tax Margin | -66.0% | -37.5% | -11.4% | -8.6% | -5.2% |
| Income Tax Expense | 7.7K | 360.7K | 428K | 402K | 45.72K |
| Net Income | (60.9M) | (45.54M) | (20.6M) | (18.88M) | (7.11M) |
| Net Margin | -65.6% | -38.3% | -13.5% | -8.9% | -3.7% |
| EPS (Basic) | (2.27) | (1.57) | (0.70) | (0.53) | (0.23) |
| EPS (Diluted) | (2.27) | (1.57) | (0.70) | (0.53) | (0.23) |
| Weighted Avg Shares | 27.01M | 30.98M | 33.91M | 41.2M | 45.13M |
| Weighted Avg Shares (Diluted) | 27.01M | 30.98M | 33.91M | 41.2M | 45.13M |
LifeMD, Inc.
NASDAQ:LFMD
Intrinsic Alpha fair value
Locked
Current Price
$1.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.